RutikaMehtaMD

Oncology • New York, NY

Gastrointestinal Cancer, Hematologic Oncology

Physician

Join to view full profile

Dr. Mehta is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Mehta's full profile

Already have an account?

Office
1305 York Ave
Fl 12
New York, NY 10021
Phone+1 646-962-6200

Education & Training

Johns Hopkins UniversityResidency, Internal Medicine, 2011 - 2014
Topiwala National Medical CollegeClass of 2007
University at BuffaloFellowship, Hematology and Medical Oncology

Certifications & Licensure

NY State Medical License 2017 - 2026
FL State Medical License 2017 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Start of enrollment: 2018 Dec 20
Active, not recruiting
Phase 2
Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L) Start of enrollment: 2019 Jul 22
Active, not recruiting
Phase 2
Roles: Principal Investigator, Contact
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors Start of enrollment: 2023 Jul 13
Recruiting
Phase 2
Roles: Principal Investigator

Publications & Presentations

PubMed

8 citations
Tumor Regression Grade and Overall Survival following Gastrectomy with Preoperative Therapy for Gastric Cancer.
Andrew J Sinnamon, Michelle Savoldy, Rutika Mehta, Sean P Dineen, Luis R Peña
Annals of Surgical Oncology. 2023-06-01
22 citations
A phase 1/2 trial of ibrutinib in combination with pembrolizumab in patients with mismatch repair proficient metastatic colorectal cancer.
Dae-Won Kim, Elaine Tan, Jun-Min Zhou, Michael J. Schell, Maria Elena Martinez
British Journal of Cancer. 2021-04-07
61 citations
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline.
Manish A Shah, Erin B Kennedy, Ashley E Alarcon-Rozas, Thierry Alcindor, Angela N Bartley
Journal of Clinical Oncology. 2023-03-01

Lectures

A phase II study of TAS-102 in combination with ramucirumab in advanced, refractory gastric or gastroesophageal junction (GEJ) adenocarcinoma.
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

New Signateratm MRD Data in Gastrointestinal Cancers to Be Presented at the ASCO GI Symposium 2023January 19th, 2023
New Signatera™ MRD Data in Gastrointestinal Cancers to Be Presented at the ASCO GI Symposium 2023January 19th, 2023